Vancouver, BC - Pyng Medical Corp. (PYT: TSX .V) today announced the Company has received European CE Mark regulatory clearance to market its new and improved FASTx™ Sternal Intraosseous Device, in Europe effective immediately.

The FASTx™ Sternal Intraosseous Device is indicated for use in establishing a sternal intraosseous access route in adult and adolescent patients (12 years of age and older) that require vascular administration of drugs or fluids to facilitate emergency resuscitation.

FASTx™ Sternal Intraosseous Device is the most rapid, reliable and safe alternative to conventional IV infusion providing lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims. The Company’s lead clinical product has been re-engineered with an integrated, easy, pull-to-remove infusion tube, light and compact form factor made for single-handed use.

“These improvements were implemented in direct response to feedback from Pyng’s key customers based on real life applications on the battlefield, Hospital, and EMS environments,” said Robert Di Silvio, President and CEO. “As part of our ongoing commitment to technology innovation we’ve achieved procedural efficiencies and further enhanced the ease-of-use for our market-leading FAST1™ Intraosseous Infusion System. We have now received both Health Canada and CE Mark approvals, and submitted our application for FDA 510K clearance for our next generation FASTx Sternal Intraosseous Device,” adds Di Silvio.

About Pyng Medical Corp.
Pyng Medical Corporation is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Pyng was selected in the “2007 TSX Venture 50 Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.

The total sales for this quarter were $1,585,684, compared to $1,633,985 for the same period last fiscal year and the gross margin was $1,132,906, compared to $1,165,152 in the same period last fiscal year. Operating expenses for the three months ended December 31, 2009 totaled $1,102,161, which was a decrease of $108,980 compared to $1,211,140 for the same quarter of last fiscal year. On a percentage basis, expenses decreased from 74% of sales for the quarter ended December 31, 2008 to 69% for the same period ended December 31, 2009.

Earnings before interest, depreciation, amortization and taxes (“EBITDA”) from continuing operations were $152,590 for the quarter ended December 31, 2009, compared to EBITDA of $109,027 for the same period last fiscal year. Net income for the three months ended December 31, 2009 was $30,717, an increase of $76,706 compared to a loss of $45,989 for the same quarter last year. The significant decrease in expenses was due to the Company’s continued efforts at costs saving and expense control.

The Company generated improved cash flows of $355,989 from operating activities in this quarter compared to -$209,528 in the three months ended December 31, 2008. As at December 31, 2009, the Company had a cash balance of $383,889 and working capital of $473,849, representing an increase of $565,517 in cash and $710,038 in working capital compared to the same quarter last year.

Full audited financial results for fiscal year ended September 30, 2009 are available on SEDAR.

About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Pyng is the first company to offer an adult intraosseous infusion device, and continues to lead in resuscitation innovation with simple-to-use, and highly-effective products including FAST1® Intraosseous Infusion System, FAST1™ Intraosseous Infusion Device, T-POD® Pelvic Stabilizer, and MAT® Tourniquet.

“We have seen significant growth in our customer base and level of interest in our resuscitation products and solutions,” said Robert Di Silvio, President and CEO of the Pyng.” Our customers are expanding their commitment to our life-saving devices, and with that commitment, to support their efforts, we are expanding our local resources. The Kirkland office will allow us to deliver superior sales and support to our US customers and to the growing prospect base.”

The new office is located at:

Pyng Medical USA
5400 Carillon Point
Building 5000
4th Floor
Kirkland, Washington 98033
United States
Main tel: 425 576 4133
Main fax: 877 439 2707

About Pyng Medical Corp.
Pyng is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Pyng was selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.

For More Information

Pyng Medical Corp.
George Dorin, CFO
(604) 303-7964
www.pyng.com

The FASTx™ Sternal Intraosseous Device is indicated for use in establishing a sternal intraosseous access route in adult and adolescent patients (12 years of age and older) that require vascular administration of drugs or fluids to facilitate emergency resuscitation. FASTx™ Sternal Intraosseous Device is a rapid, reliable and safe alternative to conventional IV infusion providing lifesaving vascular access for fluid and drug resuscitation in cardiac, shock and trauma victims. The Company’s lead clinical product has been re-engineered with an integrated, easy, pull-to-remove infusion tube, light and compact form factor made for single-handed use.

“These improvements were implemented in direct response to feedback from Pyng’s key customers based on real life applications on the battlefield, Hospital, and EMS environments,” said Robert Di Silvio, President and CEO. “As part of our ongoing commitment to technology innovation we’ve achieved procedural efficiencies and further enhanced the ease-of-use for our market-leading FAST1® Intraosseous Infusion System. We have also submitted our application for European CE Mark and FDA 510K clearance for our next generation FASTx™ Sternal Intraosseous Device,” adds Di Silvio.

About Pyng Medical Corp.
Pyng Medical Corporation is the developer and manufacturer of the proprietary, award-winning FAST1® Intraosseous Infusion System. Pyng was selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1® has worldwide application for use with hospitals, emergency medical services and military forces.

Vancouver, BC – Pyng Medical Corp. (PYT: TSX .V) today released its audited fiscal 2009 results for the year ended September 30, 2009. Pyng reported fourth quarter sales were $1,718,272 and total annual sales of $6,026,177. Net loss before tax for the year was $62,904 and after tax was $246,904.

Cost of sales for the fourth quarter of 2009 was $416,034 providing a gross margin of $1,302,238 or 76%. On a year to date basis, cost of sales was $1,685,547 providing a gross margin of $4,340,630 or 72%. Total cash operating expenses for the forth quarter of 2009 increased to $1,056,369 compared to $912,167 for the fourth quarter of fiscal 2008. On a year to date basis, total cash operating expenses for fiscal 2009 increased to $3,959,236 compared to $3,265,879 for fiscal 2008.

Full audited financial results for fiscal 2008 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Vancouver, BC – Pyng Medical Corp.’s (TSX-V: PYT) (“Pyng Medical” or the “Company”) newest product, the CRIC Cricothyroidotomy Kit, has recently been granted the CE Mark to sell into the European market. The CRIC provides a rapid, one-handed Cricothyroidotomy solution including illumination and built in safety-features, all in a single compact device.

Following on this news, Pyng Medical has received its first purchase order for the CRIC from CIR Medical, a leading medical device distributor in France. The securing of this first CRIC order will serve as its introduction into the European marketplace as well as the rest of the world.

“We are very excited about this first sale of the CRIC to CIR Medical,” commented Bob DiSilvio, President and CEO of Pyng Medical. “The European market is a great place for the CRIC to be introduced and will serve as an excellent starting point to market the features and life-savings benefits of this extraordinary product.”

“CIR Medical is very happy to be distributing the CRIC Kit on behalf of Pyng Medical in France,” added Lionel Boulleret of CIR Medical. “This product will complete our product line of innovative and life-saving medical devices.”

Pyng has applied to the FDA for clearance to allow sales in the US. For more information on the CRIC Kit, please visit our website at www.pyng.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front line critical care personnel. Creators of the FAST1® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools including the T-POD® Pelvic Stabilizer and MAT® Tourniquet. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

Vancouver, BC – Pyng Medical Corporation (TSX-V: PYT) (“Pyng Medical” or the “Company”) today announced that the Company has appointed George G. Dorin as the CFO effective November 5, 2009. Mr. Dorin is a Chartered Accountant and holds a Masters Degree in Finance from the London School of Economics in England. He has been a Chief Financial Officer and Vice President Finance for several private and public companies over the last 15 years.

Mr. Dorin’s career in finance spans over twenty-five years. Most recently, he has been providing corporate finance and financial management advisory services to various industrial companies through his own firm, CANUS Capital Corporation.

“George has had a significant amount of financial management experience with internationally focused companies,” stated the CEO Robert (Bob) Di Silvio. “On behalf of the board and management of Pyng Medical, I would like to welcome him to his new role as CFO with Pyng Medical.”

About Pyng Medical Corp.
Pyng is a leader in resuscitation innovation with simple-to-use and highly effective products including the FAST1^® Intraosseous Infusion System, the FASTx^TM Sternal Intraosseous Device, T-POD^® Pelvic Stabilizer, and MAT^® Tourniquet. The Company is awaiting FDA approval of the CRIC Cricothyrotomy System which is currently under final development. The Company plans to submit an application for FDA approval of the FASTx^TM System, which is currently still under development.

For further information, please contact:
PYNG MEDICAL CORPORATION
George Dorin, Acting Chief Financial Officer
Tel. No. (604) 696-6388

For further company information please access our website: www.Pyng.com.

Vancouver, BC – Pyng Medical Corp. (the “Company”) (TSX-V: PYT) reports that Steve Law has resigned from the positions of Chief Financial Officer and Corporate Secretary of the Company. Mr. Law will continue to work with the Board and senior management in support of a smooth transition while he pursues other business interests.

The Company is in the process of searching for new candidates for the positions of Chief Financial Officer and Corporate Secretary. Until a proper replacement for Mr. Law is obtained, the Company’s current President and Chief Executive Officer, Robert Di Silvio, will act as the Company’s Chief Financial Officer for a temporary period.

Mr. O’Neill stated on behalf of the Board of Directors “We wish to thank Steve for his contributions and also to wish him well in his future endeavours.”

On behalf of the Board of Directors of Pyng Medical Corp.

“Kevin O’Neill”
Kevin O’Neill, Director
Pyng Medical Corp.

Read full article

Vancouver, BC - Pyng Medical Corp.’s (the “Company”) (PYT: TSX-V) MAT® Tourniquet is being featured in the October edition of Wired UK Magazine as one of the “Top 10 Designs for Good.”

Wired is a magazine focused on the latest in new ideas, technology, business and culture.  Based on the upcoming October 2009 release from Metropolis books, “Design Revolution: 100 Products That Empower People” by Emily Pilloton, Wired Magazine features the Top 10 of these 100 designs in their October UK edition.

“We are honored that Wired is featuring the MAT Tourniquet as one of the Top 10 Products Designed for Good,” comments Nadine Gaston, Vice President of Sales for Pyng.  “With a significant international subscription and readership base and a mission of highlighting smart trends in technologies, Wired’s feature will spotlight the innovation of the MAT Tourniquet to a wider audience.”

Featuring a full color photo, Wired’s article draws attention to life saving benefits of the MAT.  “This article, together with the inclusion in the Design Revolution book, illuminates the benefits of the MAT Tourniquet’s superior design at a time when new tourniquet protocols are being implemented world-wide.” adds Nadine.

About Wired UK Magazine
Wired is the magazine about what’s next – bringing you the people, the trends and the big ideas that will change our lives. Each month, through thought-provoking features and stunning photography, they explore the next big ideas in science, culture, business – wherever innovation and new thinking are reshaping our world.

Since the US edition of Wired launched in 1993, the magazine has been synonymous with informed and intelligent analysis, and a consistently reliable predictor of change. The UK edition, launched in April 2009, is similarly committed to bringing you the best writers and photographers; compelling long-form journalism; extraordinary photography and design; and the people, products and ideas that matter. 

About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front line critical care personnel. Creators of the FAST1^® Intraosseous Infusion System, Pyng’s expanded product portfolio includes a variety of innovative, lifesaving tools including the T-POD^® Pelvic Stabilizer and MAT^® Tourniquet. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company’s proprietary FAST1^®, the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.

www.pyng.com